anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disruptive manic and depressive episodes prevent bipolar disorder (BPD) sufferers from living healthy, functional lives. Relapse rates for BPD are high, between 70% and 90%, with approximately half of those relapses occurring in the first 2 years after remission. High rates of relapse and no substantial improvements in illness outcomes for many patients despite advances in drug treatment may be related to a common problem: medication nonadherence. Nine in 10 individuals with BPD have seriously considered medication withdrawal, and one third of individuals with BDP do not take 30% or more of their prescribed medications. The researchers in this study will identify BPD patients who do not take their medications as prescribed and conduct interviews with them. By obtaining an understanding of subjective reasons for medication nonadherence, this study will pave the way for better interventions to ensure BDP patients take the medications that will help them.

Participation in this study will consist of a single visit, lasting between 1.5 and 3 hours. All participants will have a history of medication nonadherence. Participants will be asked to fill out questionnaires and undergo a structured interview with a researcher. The interview will be audio recorded. The questionnaires and interview will assess BPD symptoms, attitudes toward medications, and to what extent patients are taking their medications. Researchers will also measure the number of pills used in participants' prescriptions by counting how many pills are left in each prescription bottle.
Patients in this group will receive only a complete decongestive treatment program consisting manual lymph drainage, multilayer bandaging, skin/nail care, and exercise treatments. The treatment will last 45 minutes/session, 5 sessions/week and 3 weeks.
One of the primary focuses of newer potential cancer treatment discovery is maximized efficacy with minimal side effects. The extent to which many standard of care cancer-fighting treatments can be administered to a patient is limited by the side effects, which are often lethal with extended dosing.  As such, researchers are looking more toward naturally occurring molecules and treatments with minimal or no side effects. Tocotrienols, a naturally occurring molecule found in red palm and other plants, have been studied extensively due to their anti-cancer properties. Dichloroacetate has also been more recently studied for it's cancer-fighting properties and presents an opportunity for synergistic efficacy when coupled with tocotrienol, both by formulation and by chemical linking. With synergistic combinations of potential treatments, newer treatment mechanisms can be achieved with higher efficacy and a resulting minimization or complete lack of side effects.
PURPOSE: A cosmetic composition containing natural extract for preventing hair loss and promoting hair growth is provided to promote blood circulation of scalp and relieve scalp inflammation without side effects. CONSTITUTION: A composition for promoting hair growth and preventing hair loss contains 200-400 weight parts of saw palmetto extract, 200-400 weight parts of Althaea rosea Cav. Extract, and 200-400 weight parts of Portulaca olearacea L. extract based on 100 weight parts of walnut extract. The extract is isolated using ultrasonic wave at 4500kHz for 20 minutes. A cosmetic composition for preventing hair loss and promoting hair growth contains 1-50 weight% of the composition and remaining amount of cosmetic base. The cosmetic base is shampoo, rinse, treatment or tonic.
OBJECTIVE: Investigate the acceptability of Specialist Psychotherapy with Emotion for Anorexia in Kent and Sussex (SPEAKS), a novel intervention for anorexia nervosa (AN), conducted as a feasibility trial to provide an initial test of the intervention.
METHODS: SPEAKS therapy lasting 9-12 months was provided to 34 people with AN or atypical AN by eight specialist eating disorder therapists trained in the model across two NHS Trusts in the UK (Kent and Sussex) during a feasibility trial. All participants were offered a post-therapy interview; sixteen patients and six therapists agreed. All patient participants were adult females. Interviews were semi-structured and asked questions around individuals' experience of SPEAKS, the acceptability of the intervention and of the research methods. Interviews were analyzed using thematic analysis.
RESULTS: Key areas explored in line with research questions led to 5 overarching themes and 14 subthemes: (1) shift in treatment focus and experience, (2) balancing resources and treatment outcomes, (3) navigating the online treatment environment, (4) therapist adaptation and professional development, and (5) research processes.
DISCUSSION: SPEAKS was found to be an acceptable intervention for treating AN from the perspective of patients and therapists. The findings provide strong support for delivery of a larger scale randomized control trial. Recommendations for future improvements, particularly pertaining to therapist understanding of the treatment model are detailed, alongside broader clinical implications.
PUBLIC SIGNIFICANCE: We aimed to evaluate the acceptability of a new anorexia nervosa treatment called SPEAKS. Interviews were conducted with patients and therapists involved in the pilot study and responses were analyzed. Results showed that both patients and therapists found SPEAKS to be an acceptable treatment for anorexia nervosa. The study suggests that SPEAKS meets the criteria for moving forward with a larger trial to assess its effectiveness.
In one embodiment, the present invention is directed to a first oligonucleotide comprising the sequence of or derived from 5 -CTAGGGCGGGCGGGACTCACCTAC-3 or the nucleic acid sequence complementary thereto. The first oligonucleotide can be used with a nucleic acid of between 15 and 30 nucleotides that does not comprise the sequence of the first oligonucleotide and is found in the region from Vbgr; to Jbgr; of the Vbgr;13.1 gene in Vbgr;13.1 T cells, wherein the sequences of the oligonucleotide and the nucleic acid are not found on the same strand of the Vbgr;13.1 gene pair, to amplify a portion of the Vbgr;13.1 gene. Alternatively, the first oligonucleotide can be used with a labeling moiety in methods of detecting a LGRAGLTY motif found in T cell receptors of Vbgr;13.1 T cells. This motif is associated with autoimmune diseases, such as multiple sclerosis (MS). Once the motif is detected, the autoimmune disease can be treated or its progress monitored. The autoimmune disease can be treated by administering one ore more peptides comprising the LGRAGLTY motif.
It will be a randomized control trial study in which data are collected from Jinnah hospital Lahore. A sample of 26 patients will be included and divided into two group. One group of 13 patients will receive early mobilization with chest physiotherapy and other group of 13 patients will receive early mobilization only. All subject will receive 30 minute two session per day till two weeks. Outcome will be measured with MRC dyspnea scale and Pulmonary function test with spirometry to measure FEV1 and FEV1/FVC and quality of life will be checked by using ST. GEORGE'S respiratory questionnaire. Data will be analyzed by using SPSS version 21.
Process for detection or assay of immunoglobulin-reagins antagonists to certain allergens, wherein the sample, e.g. a body fluid such as blood plasma or serum, is mixed with particles of an insol. polymer (e.g.Sephadex) to which the test allergen(s) has been firmly (covalently) fixed. The polymer, with the reagin now attached to the allergen, is brought into contact with specific antibodies to the reagin which have been marked (e.g. with a radiolabel such as 125I, or contg. a fluorescent gp.) and the polymer (or supernatant fluid) assayed for the marker. Alternatively, reagin may be marked instead of the antibodies and the polymer finally treated with this. For in vitro diagnosis of hypersensitivity.
The present invention relates to an apparatus for generating a welfare care schedule. The apparatus includes a communication interface and a processor operably connected with the communication interface. The processor receives a health care request form or questionnaire for a subject through the communication interface, and decides contents which are matched with at least one item of a treatment goal, a treatment period, a treatment method, and manager information by using items of the health care request form or questionnaire. To a manager's device, provided are a first screen on which the health care request form or questionnaire is displayed, and a second screen which is disposed adjacent to the first screen and displays information determined for at least one of the treatment goal, treatment period, treatment method, and manager information. An opinion on the subject is obtained from the manager's device to create a care plan for the subject. The present invention can shorten the time required to create the care plan.
PROBLEM TO BE SOLVED: To prepare the subject cosmetic containing three kinds of specific substances, mutually not interfering their actions, synthetically stimulating the functions of skin and excellent in a skin ageing-preventing effect. SOLUTION: This cosmetic contains (A) a fibroblast collagen synthesis- stimulating substance, (B) a fibroblast collagenase production-stimulating substance, and (C) an epidermal cell ceramide synthesis-stimulating substance. The component A includes one or more kinds of ascorbic acid (derivatives). The component B includes serine (derivatives), ethanolamine (derivatives), silk partially hydrolysates, silicic acid-related substances and their salts. The component C includes nicotinic acid (derivatives) and nicotinyl alcohol (salts). The components are preferably compound is amounts of 0.01-10wt.%, 0.001-10wt.% and 0.001-10wt.%, respectively, based on the whole amount of the cosmetic. Thereby, the cosmetic enhances the metabolism rotation of collagen, activates the synthesis of ceramide, and gives the objective effects.
The utility model provides a skin care film, which comprises a protective layer, a glue layer, a spacing layer and an attached layer. The protective layer includes a protective film. The glue layer is connected with the protective layer and comprises a glue film. The spacing layer is connected with the glue layer and comprises a spacing film. The attaching layer is connected with the spacing layer and comprises an attaching film. Thus, a skin care film which can suppress bacteria and suppress odor is provided.
The study is designed to evaluate the efficacy and safety of "Bisphosphonate Therapy for Osteogenesis Imperfecta (OI)." OI is an inherited disorder of collagen synthesis. Collagen is the major structural protein of the matrix of tendons, skin, and bones. Affected persons have low bone mineral density (and experience multiple fractures and progressive bony deformity). In its most severe form, the disorder is lethal in infancy. We plan to characterize the changes effected by oral bisphosphonate therapy and compare them to a regimen of intravenous bisphosphonate therapy in a group of children with OI.

Additionally, we have begun to treat patients with OI and other conditions of low bone mineralization for age who are not eligible for the standard protocol (too young, history of abdominal pain, etc.) with bisphosphonate. We also plan to screen the parents and siblings of our patients diagnosed with osteogenesis imperfecta, in order to determine if they also have osteoporosis.
Oral temperature measurements for subjects age Group C as 5 years or older. Both febrile and non-febrile subjects included in this arm.
Inguinal hernia repair is performed more than 20 million times per annum, representing a significant health and economic burden. Over the last three decades, significant technical advances have started to reduce the invasiveness of these surgeries, which translated to better recovery and reduced costs. Here we bring forward an innovative surgical technique using a biodegradable cyanoacrylate glue instead of a traumatic suture to close the peritoneum, which is a highly innervated tissue layer, at the end of endoscopy hernia surgery. To test how this affects the invasiveness of hernia surgery, we conducted a cohort study. A total of 183 patients that underwent minimally invasive hernia repair, and the peritoneum was closed with either a conventional traumatic suture (n = 126, 68.9%) or our innovative approach using glue (n = 57, 31.1%). The proportion of patients experiencing acute pain after surgery was significantly reduced (36.8 vs. 54.0%, p = 0.032) by using glue instead of a suture. In accordance, the mean pain level was higher in the suture group (VAS = 1.5 vs. 1.3, p = 0.029) and more patients were still using painkillers (77.9 vs. 52.4%, p = 0.023). Furthermore, the rate of complications was not increased in the glue group. Using multivariate regressions, we identified that using a traumatic suture was an independent predictor of acute postoperative pain (OR 2.0, 95% CI 1.1-3.9, p = 0.042). In conclusion, suture-less glue closure of the peritoneum is innovative, safe, less painful, and possibly leads to enhanced recovery and decreased health costs.
During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
Amoxicillin and Clavulanate Potassium for Oral Suspension 250 mg/62.5 mg per 5 mL may be taken every 8 hours or every 12 hours, depending on the strength of the product prescribed. Each dose should be taken with a meal or snack to reduce the possibility of gastrointestinal upset. Many antibiotics can cause diarrhea. If diarrhea is severe or lasts more than 2 or 3 days, call your doctor.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

Keep suspension refrigerated. Shake well before using. When dosing a child with Amoxicillin and Clavulanate Potassium for Oral Suspension 250 mg/62.5 mg per 5 mL, use a dosing spoon or medicine dropper. Be sure to rinse the spoon or dropper after each use. Bottles of Amoxicillin and Clavulanate Potassium for Oral Suspension 250 mg/62.5 mg per 5 mL may contain more liquid than required. Follow your doctor's instructions about the amount to use and the days of treatment your child requires. Discard any unused medicine.

Patients should be counseled that antibacterial drugs including Amoxicillin and Clavulanate Potassium for Oral Suspension 250 mg/62.5 mg per 5 mL, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Amoxicillin and Clavulanate Potassium for Oral Suspension 250 mg/62.5 mg per 5 mL is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Amoxicillin and Clavulanate Potassium for Oral Suspension 250 mg/62.5 mg per 5 mL or other antibacterial drugs in the future.
PROBLEM TO BE SOLVED: To obtain the subject agent, whose bioavailability is improved by increasing water-solubility of JM216, a carcinostatic platinum complex. SOLUTION: This agent is a new JM216 suppository dosage form prepared by including amorphous JM216 in a pharmaceutical dosage form. The amorphous JM216 is obtained by grinding down powdered JM216 with a β-cyclodextrin or polymer selected from the group consisting of gelatin, polyvinylpyrrolidinone and hydroxypropyl methyl cellulose, for a sufficient time to convert the JM216 into the amorphous state. The wt. ratio of the JM216 to the β-cyclodextrin or polymer is (1:1) to (1:15). This can eliminate or alleviate a side effect, e.g. nausea or vomiting, which may be involved in the oral administration.
Patients with non-Hodgkin's lymphoma arising primarily in bone have been studied using a number of different names making literature searching difficult. The term Osteolymphoma has been proposed to make searching easier in the future. Patients in this study undergoing staging which includes isotope bone scanning and PET scanning where available. Eligible patients then undergo treatment with three cycles of CHOP chemotherapy at conventional doses and shrinking field radiotherapy to a total of 45 Gy. Monoclonal antibodies are not included as good results have been obtained without using them. After treatment the patients are regularly monitored. The trial is presented twice per year at the meetings of TROG, ALLG and AROLG.
The present disclosure provides a system for real-time health monitoring of one or more users. The system includes a computing device associated with a facility, a plurality of cameras, an AI edge device, and a communication network. Moreover, the system includes a server, a database, and a notification interface. The AI edge device monitors the health of one or more users in real-time. The AI edge device monitors the health of the one or more users by processing a video feed captured by the plurality of cameras. Further, the AI edge device notifies the health-related issues in real-time using the notification interface to a first set of users.
BACKGROUND: The Coronavirus disease 2019 (COVID-19) pandemic has emerged as a global health crisis, with clinical manifestations including those suggesting injury to various organs such as the ovaries, which implies that it extends beyond respiratory infections. Changes in gut microbiota may exhibit correlations with the mechanisms and stages of severity in COVID-19, as well as a link with sex hormones, embryo development, and pregnancy. Controlled ovarian stimulation (COS) is used to induce the development of multiple high-quality follicles during in vitro fertilization (IVF). Our research aimed to investigate whether patients infected with COVID-19 have altered gut microbiota compositions that would affect the outcomes of COS.
METHODS: Twenty-one healthy females and seventeen patients with COVID-19 were enrolled. Samples were sequenced for gut microbiota identification through 16 S rRNA V3-V4 region, including species annotation, community diversity, and community functions.
RESULTS: No significant differences were found between the groups in terms of in IVF cycle outcomes and laboratory parameters. Patients with COVID-19 and healthy women showed no significant difference in the total number of available blastocyst embryos. Furthermore, the gut microbiota alpha diversity index in the COVID-19 group were markedly reduced compared to those of healthy females. Comparing the COVID-19 group to the controls, the gut microbiota dysbiosis decreased levels of Ruminococcus, and Agathobater, and elevated levels of Achromobacter and Raistonia. Finally, we identified a series of microbial functional characteristics, including membrane transport and carbohydrate metabolism, that exhibited significant disparities between the two groups.
CONCLUSIONS: Patients in the COVID-19 group exhibited significant disparities in the gut microbiota composition compared to the healthy women during COS. However, the IVF outcomes did not show any significant differences between the two groups. Collectively, our speculation suggests that SARS-COV-2 infection may alter the gut microbiota without impacting IVF outcomes.
Methemoglobinemia has been reported in patients receiving other organic nitrates, and it probably could also occur as a side effect of ISMN. Certainly nitrate ions liberated during metabolism of ISMN can oxidize hemoglobin into methemoglobin. Even in patients totally without cytochrome b5 reductase activity, however, and even assuming that the nitrate moiety of ISMN is quantitatively applied to oxidation of hemoglobin, about 2 mg/kg of ISMN should be required before any of these patients manifest clinically significant (≥ 10%) methemoglobinemia. In patients with normal reductase function, significant production of methemoglobin should require even larger doses of ISMN. In one study in which 36 patients received 2 to 4 weeks of continuous nitroglycerin therapy at 3.1 to 4.4 mg/hr (equivalent, in total administered dose of nitrate ions, to 7.8-11.1 mg of ISMN per hour), the average methemoglobin level measured was 0.2%; this was comparable to that observed in parallel patients who received placebo.

Not withstanding these observations, there are case reports of significant methemoglobinemia in association with moderate overdoses of organic nitrates. None of the affected patients had been thought to be unusually susceptible.

Methemoglobin levels are available from most clinical laboratories. The diagnosis should be suspected in patients who exhibit signs of impaired oxygen delivery despite adequate cardiac output and adequate arterial pO2. Classically, methemoglobinemic blood is described as chocolate brown, without color change on exposure to air.

When methemoglobinemia is diagnosed, the treatment of choice is methylene blue, 1 to 2 mg/kg intravenously.